Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anesiva, Inc.

https://www.anesiva.com/

Latest From Anesiva, Inc.

CEO Vounatsos, Aduhelm Commercial Team To Exit As Biogen Shifts Focus

The company will prioritize later-stage R&D, including potential accelerated approval for a second anti-amyloid antibody, while replacing its CEO and cutting Aduhelm commercial operations and other costs.

Strategy Sales & Earnings

Shilpa Medicare’s Plan For Eylea Biosimilar Spells Ambition, But Path Not Easy

Shilpa Medicare’s plan for trials of an Eylea biosimilar shows the company’s ambition to leapfrog to a biosimilars-led growth strategy, one that Indian majors like Cipla and Lupin pivoted to post a successful generics program. However, the path isn’t going to be easy and Biocon/Viatris, Samsung Biologics are ahead

Research & Development Biosimilars

Biogen Exits Joint Venture As Samsung Biologics Buys Out Bioepis

Biogen’s stake in Samsung Bioepis has been fully acquired by former partner Samsung Biologics, following an announcement of the deal in January.

Deals Biosimilars

Samsung Biologics Sees Biosimilars As One Of Three Key Pillars

Samsung Biologics has reiterated the importance of biosimilars to its business in the wake of its move to buy out partner Biogen’s stake in their Samsung Bioepis biosimilars joint venture.

Strategy Biosimilars
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • AlgoRx Pharmaceuticals
    • Corgentech
UsernamePublicRestriction

Register